Genetic Technologies (GENE) Competitors $0.76 0.00 (0.00%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends GENE vs. NRXP, HCWB, SNSE, AVTX, PMCB, AWH, IPA, WENA, TSBX, and TRIBShould you be buying Genetic Technologies stock or one of its competitors? The main competitors of Genetic Technologies include NRx Pharmaceuticals (NRXP), HCW Biologics (HCWB), Sensei Biotherapeutics (SNSE), Avalo Therapeutics (AVTX), PharmaCyte Biotech (PMCB), Aspira Women's Health (AWH), ImmunoPrecise Antibodies (IPA), ANEW Medical (WENA), Turnstone Biologics (TSBX), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry. Genetic Technologies vs. NRx Pharmaceuticals HCW Biologics Sensei Biotherapeutics Avalo Therapeutics PharmaCyte Biotech Aspira Women's Health ImmunoPrecise Antibodies ANEW Medical Turnstone Biologics Trinity Biotech NRx Pharmaceuticals (NASDAQ:NRXP) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk. Do insiders and institutionals have more ownership in NRXP or GENE? 4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genetic Technologies shares are held by institutional investors. 19.0% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 6.5% of Genetic Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is NRXP or GENE more profitable? Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A -377.62% Genetic Technologies N/A N/A N/A Does the media favor NRXP or GENE? In the previous week, Genetic Technologies had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 7 mentions for Genetic Technologies and 5 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.17 beat Genetic Technologies' score of -0.11 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genetic Technologies 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, NRXP or GENE? Genetic Technologies has higher revenue and earnings than NRx Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx PharmaceuticalsN/AN/A-$30.15M-$2.69-0.42Genetic Technologies$5.03M0.74-$7.88MN/AN/A Which has more volatility & risk, NRXP or GENE? NRx Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Does the MarketBeat Community prefer NRXP or GENE? Genetic Technologies received 150 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 55.33% of users gave Genetic Technologies an outperform vote. CompanyUnderperformOutperformNRx PharmaceuticalsOutperform Votes11100.00% Underperform VotesNo VotesGenetic TechnologiesOutperform Votes16155.33% Underperform Votes13044.67% Do analysts prefer NRXP or GENE? NRx Pharmaceuticals currently has a consensus target price of $31.50, indicating a potential upside of 2,663.16%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe NRx Pharmaceuticals is more favorable than Genetic Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Genetic Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryNRx Pharmaceuticals beats Genetic Technologies on 9 of the 14 factors compared between the two stocks. Ad Porter & CompanyThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. Get Genetic Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GENE vs. The Competition Export to ExcelMetricGenetic TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.71M$3.10B$5.34B$8.91BDividend YieldN/A1.76%4.98%4.03%P/E RatioN/A46.44135.6617.44Price / Sales0.74390.161,262.7694.87Price / CashN/A179.8138.9536.42Price / Book3.064.426.305.91Net Income-$7.88M-$42.42M$118.43M$224.86M7 Day PerformanceN/A-4.29%-1.58%-0.59%1 Month Performance1.00%3.36%3.00%4.03%1 Year Performance-78.14%36.16%36.17%27.01% Genetic Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GENEGenetic Technologies0.1015 of 5 stars$0.77flatN/AN/A$3.71M$5.03M0.0050Short Interest ↑NRXPNRx Pharmaceuticals2.0659 of 5 stars$1.32+0.8%N/A-96.3%$14.08MN/A-0.492Short Interest ↑News CoverageHCWBHCW Biologics1.83 of 5 stars$0.37-11.9%N/A-78.0%$14.00M$2.84M-0.3640Short Interest ↓News CoveragePositive NewsGap DownSNSESensei Biotherapeutics4.7481 of 5 stars$0.56+3.7%N/A-29.1%$13.98MN/A-0.4740Upcoming EarningsNews CoverageGap DownAVTXAvalo Therapeutics2.2424 of 5 stars$13.31+3.1%N/A-38.6%$13.86M$1.92M0.0040Short Interest ↓PMCBPharmaCyte Biotech1.2189 of 5 stars$1.80-0.6%N/A-15.8%$13.83MN/A2.732Short Interest ↑AWHAspira Women's Health1.6037 of 5 stars$0.86flatN/A-78.0%$13.81M$9.15M-0.59110Analyst ForecastShort Interest ↑News CoverageGap UpIPAImmunoPrecise Antibodies2.6827 of 5 stars$0.44flatN/A-69.0%$12.69M$18.16M-0.5680Short Interest ↑WENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AUpcoming EarningsGap UpTSBXTurnstone Biologics3.9275 of 5 stars$0.53+1.9%N/A-70.3%$12.35M$19.31M-0.1582Earnings ReportNews CoveragePositive NewsGap DownTRIBTrinity Biotech1.9022 of 5 stars$1.61-4.2%N/A-26.2%$12.27M$58.65M-0.60480Short Interest ↓News Coverage Related Companies and Tools Related Companies NRXP Alternatives HCWB Alternatives SNSE Alternatives AVTX Alternatives PMCB Alternatives AWH Alternatives IPA Alternatives WENA Alternatives TSBX Alternatives TRIB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GENE) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genetic Technologies Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Genetic Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GENE Stock Alerts